ReviewAAPS PharmSciTech2022
Cell-Penetrating Peptides as Passive Permeation Enhancers for Transdermal Drug Delivery.
Review in AAPS PharmSciTech, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Fluorous oligoarginines as supra-enhancers for intracellular and transdermal peptide delivery.Bioactive materials · 2026Article
- Biomimetic Protein Materials for Adjuvant-Free Dermal Penetration.ACS materials letters · 2026Article
- Preparation of Dual-Drug-Loaded Liver-Targeted Liposomes Co-Modified with SP94 Peptide and TAT Peptide.Current drug delivery · 2026Article
- Biomimetic dual-crosslinked GelMA-SilMA hydrogel microneedle for delivering DSPE-PEG2K-TAT-modified quercetin liposomes to treat rheumatoid arthritis via the caspase-8/caspase-3/GSDME pathway.Journal of nanobiotechnology · 2025Article
- Research progress and strategies for the biosynthesis of keratinocyte growth factor-2 (KGF-2) inPeerJ · 2025Review
- Advances in peptide-based drug delivery systems.Heliyon · 2024Review
- Molecular farming expression of recombinant fusion proteins applied to skincare strategies.PeerJ · 2024Review
- Efficient Colon Cancer Immunogene Therapy Through Co-Delivery of IL-22BP mRNA and Tumor Cell Lysate by CLSV Nanoparticles.International journal of nanomedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-penetrating peptides have been widely used as a tool to gain access to cytosol for numerous applications. The review highlights the advances made in preclinical and clinical research using cell-penetrating peptides since their discovery in 1980s. Further, the emphasis is on summarizing the role of cell-penetrating peptides as permeation enhancers for transdermal and topical drug delivery applications. A summary table of preclinical studies utilizing various peptides in combination with different active ingredients and drug delivery systems is included. Lastly, we capture the challenges associated with the cell-penetrating peptides to translate the preclinical work to clinical applications.
Indexed as
Identifiers
36163537What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.